Resmed Inc: (NYSE: RMD)

$49.72

-0.36 (-0.72%)

Volume 604,735

May 22 04:04 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Balance Sheet

Get Balance Sheet for:

Annual Balance Sheet

Fiscal Year End for RESMED INC falls in the month of June.

All items in Millions except Per Share data.

06/30/12 06/30/11 06/30/10 06/30/09 06/30/08
Assets          
Cash & Equivalents 810 735 489 416 321
Receivables 285 284 232 214 192
Notes Receivable 0 0 0 0 0
Inventories 174 201 186 157 158
Other Current Assets 111 87 79 66 68
Total Current Assets 1,361 1,292 985 853 739
Net Property & Equipment 434 462 387 378 357
Investments & Advances 0 0 0 4 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 24 19 19 19 16
Intangibles 311 283 230 248 281
Deposits & Other Assets 8 12 5 5 8
Total Assets 2,138 2,069 1,626 1,508 1,406
Liabilities & Shareholders Equity 06/30/12 06/30/11 06/30/10 06/30/09 06/30/08
Notes Payable 0 0 0 0 0
Accounts Payable 55 55 58 48 56
Current Portion Long-Term Debt 0 0 122 68 44
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 127 104 81 67 61
Income Taxes Payable 29 5 23 57 4
Other Current Liabilities 42 45 30 29 27
Total Current Liabilities 253 209 313 269 193
Mortgages 0 0 0 0 0
Deferred Taxes/Income 23 25 24 26 34
Convertible Debt 0 0 0 0 0
Long-Term Debt 251 100 0 94 94
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 4 3 3 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 530 338 339 393 324
Shareholders Equity 06/30/12 06/30/11 06/30/10 06/30/09 06/30/08
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 0 0 0
Capital Surplus 900 798 660 523 468
Retained Earnings 1,367 1,112 885 695 548
Other Equity 236 324 86 106 208
Treasury Stock 896 505 345 209 143
Total Shareholder's Equity 1,608 1,731 1,288 1,115 1,082
Total Liabilities & Shareholder's Equity 2,138 2,069 1,626 1,508 1,406
Total Common Equity 1,608 1,731 1,288 1,115 1,082
Shares Outstanding 142.70 152.90 151.60 150.70 154.50
Book Value Per Share 11.27 11.32 8.49 7.40 7.00

Quarterly Balance Sheet

Fiscal Year End for RESMED INC falls in the month of June.

All items in Millions except Per Share data.

03/31/13 12/31/12 09/30/12 06/30/12 03/31/12
Assets          
Cash & Equivalents 1,013 958 891 810 776
Receivables 300 285 270 285 271
Notes Receivable 0 0 0 0 0
Inventories 166 195 193 174 183
Other Current Assets 126 114 122 111 109
Total Current Assets 1,580 1,530 1,450 1,361 1,326
Net Property & Equipment 444 440 438 434 443
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 18 19 18 24 21
Intangibles 328 338 333 311 327
Deposits & Other Assets 5 4 6 8 12
Total Assets 2,375 2,330 2,245 2,138 2,129
Liabilities & Shareholders Equity 03/31/13 12/31/12 09/30/12 06/30/12 03/31/12
Notes Payable 0 0 0 0 0
Accounts Payable 49 52 53 55 55
Current Portion Long-Term Debt 340 0 0 0 1
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 128 135 132 127 123
Income Taxes Payable 19 20 25 29 35
Other Current Liabilities 44 44 43 42 44
Total Current Liabilities 580 251 253 253 257
Mortgages 0 0 0 0 0
Deferred Taxes/Income 22 23 23 23 24
Convertible Debt 0 0 0 0 0
Long-Term Debt 1 301 266 251 235
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 3 4 3 3 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 607 579 546 530 520
Shareholders Equity 03/31/13 12/31/12 09/30/12 06/30/12 03/31/12
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 992 960 933 900 861
Retained Earnings 1,528 1,467 1,414 1,367 1,290
Other Equity 259 267 255 236 264
Treasury Stock 1,011 944 904 896 807
Total Shareholder's Equity 1,768 1,752 1,699 1,608 1,609
Total Liabilities & Shareholder's Equity 2,375 2,330 2,245 2,138 2,129
Total Common Equity 1,768 1,752 1,699 1,608 1,609
Shares Outstanding 143.40 143.00 142.00 142.70 144.10
Book Value Per Share 12.33 12.25 11.96 11.27 11.17
Quick Links

Services

My Account

Resources

Client Support

Follow Us

Facebook

Twitter

Linkedin

RSS

You Tube

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.

Copyright 2013 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.